The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review

Figures & data

Table 1. The main characteristics of studies included in this meta-analysis.

Study	Tumor type	Country	Sample size	Detection method	Reference controls	Cutoff value	HR (95% CI) for OS	Multivariate analysis	Follow-up (months)	Treatment	NOS score	Reference
Deng. HH 2019	RCC	China	49	RT-qPCR	GAPDH	median	1.40 (1.02–1.91)	No	NA	Surgery	7	[18]
Huang HG 2020	GC	China	80	RT-qPCR	GAPDH	mean	1.41 (1.06–1.87)	No	NA	Surgery	7	[22]
Liu. L 2019	BC	China	98	RT-qPCR	GAPDH	median	1.54 (1.02–2.33)	No	NA	Surgery+ Radiotherapy	7	[9]
Lu. GM 2018	BC	China	39	RT-qPCR	GAPDH	mean	1.55 (1.12–2.14)	No	NA	Surgery	6	[10]
Mao. BD 2019	CC	China	84	RT-qPCR	GAPDH	median	1.46 (1.01–2.11)	No	60	Surgery	7	[11]
Qiao. SC 2019	Osteosarcoma	China	45	RT-qPCR	β-actin	median	0.038 (0.005–0.293)	Yes	NA	Surgery+ Chemotherapy	6	[13]
Sun. CC 2016	NSCLC	China	124	RT-qPCR	GAPDH	P25	7.19 (3.53–10.56)	Yes	NA	Surgery	7	[14]
Wang. J 2019	OC	China	80	RT-qPCR	GAPDH	NA	1.69 (3.53–10.56)	No	37	Surgery	7	[8]
Wang. B 2019	Glioma	China	82	RT-qPCR	GAPDH	mean	2.531 (1.532–4.183)	Yes	NA	Non	7	[7]
Wang. RP 2019	HCC	China	127	RT-qPCR	GAPDH	median	3.016 (1.216–3.889)	Yes	NA	Surgery	7	[15]
Yu. CL 2019	CC	China	92	RT-qPCR	GAPDH	median	2.895 (1.446–5.797)	Yes	NA	Surgery	7	[12]
Zhao. XH 2018	PDAC	China	140	RT-qPCR	GAPDH	NA	2.258 (1.989–2.563)	Yes	NA	Surgery	7	[19]

Abbreviation: HR: Hazard ratios; OS: overall survival; RCC: Renal cell carcinoma; BC: Breast cancer; CC: Cervical cancer; NSCLC: Non-small cell lung cancer; OC: Ovarian cancer; HCC: Hepatocellular carcinoma; PDAC: Pancreatic ductal adenocarcinoma;

Figure 1. Flow diagram of the study selection.

Figure 2. Forest plots of the association between LINC00511 expression level and overall survival in patients with malignant tumors(a); Kaplan-Meier survival analysis of LINC00511 expression for overall survival (b) and disease-free survival (c).

Figure 3. Forest plots of the association between LINC00511 expression level and lymph node metastasis.

Figure 4. Sensitivity analysis of overall survival (a) and metastasis (b); Begg’s funnel plots of OS (c) and lymph node metastasis (d).

Table 2. Clinical significance and biological functions of LINC00511 and the relevant molecular mechanisms in malignant tumors.

Tumor types	Tumor cell lines	Expression in tumor tissues and cell lines	Clinical significance of dysregulation	Related cell processes	Direct or indirect targets	References
Renal cell Cancer	A498, 786-O, ACHN and Caki-2	Increased	Advanced tumor stage, higher incidence of lymph node metastasis; Worse OS.	Facilitate proliferation, colony formation, cell cycle progression, and metastasis, and repress apoptosis in vitro; Accelerate tumor growth in vivo.	miR-625/CCND1	[18]
Gastric cancer	AGS, SGC7901, BGC823, MKN45 and MGC803	Increased	Advanced tumor stage, Larger tumor size; Worse OS and DFS.	Facilitate tumor cell proliferation, migration and invasion, and repress apoptosis in vitro; Accelerate tumor growth in vivo.	miR-515-5p; miR-625-5p/NFIX p38, ERK1/2 and JNK, miR-124-3p/EZH2	[20–22]
Breast cancer	MDA-MB-231, MDA-MB-436, MDA-MB-468, MDA-MB-453, and MCF-7	Increased	Higher incidence of lymph node metastasis, distant metastasis and recurrence, larger tumor size, and advanced tumor stage; Worse OS.	Facilitate proliferation, cell cycle progression, sphere-formation ability, invasion, resistance to radio therapy and repress apoptosis in vitro; Accelerate tumor growth in vivo and promote resistance to radio therapy in vivo.	miR-185-3p/E2F1/Nanog, miR-185-3p/STXBP4, EZH2/PRC2/CDKN1B	[9,10,28,32]
Glioma	U87, LN229, U251 and A172	Increased	Higher WHO grade and KPS score; Worse OS and DFS.	Facilitate proliferation, migration, invasion and EMT in vitro; Accelerate tumor growth in vivo.	miR-124-3p/CCND2 miR-524-5p/YB1/ZEB1,	[26,27]
Hepatocellular carcinoma	SMCC7721, HepG2,Hep3B MHCC-97 H, Huh7, HCC-LM3 and MHCC-97 L	Increased	Advanced tumor stage, higher incidence of lymph node metastasis and vascular invasion; Worse OS.	Facilitate proliferation, cell cycle progression colony formation and invasion and repress apoptosis in vitro.	miR-195/EYA1, miR-424, miR-29 c	[15–17]
Pancreatic ductal adenocarcinoma	PANC-1, MIA PaCa-2, Capan-2, SW1990, ASPC-1 and BxPC-3	Increased	Higher incidence of lymph node metastasis and early recurrence; Worse OS.	Facilitate proliferation, migration, invasion and angiogenesis.	miR-29b-3p/VEGFA	[19]
Non-small-cell lung cancer	A549, SK-MES-1, H1299, 95D, H460, H520, H1975, H157, SK-LU-1, and SPC-A-1	Increased	Large tumor size, Advanced tumor stage, and higher incidence of lymph node metastasis; Worse OS.	Facilitate proliferation, invasion metastasis, and EMT, and repress apoptosis in vitro; Accelerate tumor growth in vivo.	EZH2/PRC2/p57, PTEN/AKT/FOXO1, EZH2/KLF2, EZH2/LATS2, LSD1/LATS2, LSD1//KLF2	[14,33,37]
Thyroid cancer	B-CPAP, KTC-1, TPC-1, BCPAP and IHH-4	Increased	Large tumor size and higher incidence of lymph node metastasis	Facilitate proliferation, cell cycle progression migration, invasion, and repress apoptosis and radiosensitivity in vitro.	CDK2, CDK4, EZH2, TAF1/JAK2/STAT3	[24,34]
Ovarian cancer	CAOV3, OVCAR3 SKOV3, and UWB1.289	Increased	Large tumor size, Advanced tumor stage, and higher incidence of lymph, node metastasis, poor differentiation; Worse OS.	Enhance cell viability and invasion, and decrease apoptosis in vitro	miR-424-5p, miR-370-5p, EZH2/P21	[29,35]
Cervical cancer	SiHa, HeLa, C33A and Caski	Increased	Large tumor size, Advanced tumor stage, and higher incidence of lymph, node metastasis, distant metastasis and squamous cell carcinoma; Worse OS.	Facilitate proliferation, cell cycle progression, migration, invasion, and resistance to paclitaxel, and repress apoptosis and autophagy	RXRA/PLD1,MMP-2, MMP-9, P-GP, Bcl-2, MRP1, Bax and active caspase-3	[11,12,36]
Tongue squamous cell carcinoma	Tca-8113, SCC-9 SCC-4 and CAL-27	Increased	Not been studied	Facilitate proliferation and invasion in vitro	miR-765 m/LAMC2	[23]
Osteosarcoma	MG-63, HOS, Saos-2 and 143B	Increased, Decreased	Increased tumor cell necrosis rate to neoadjuvant chemotherapy; Better OS.	Facilitate proliferation, colony formation, and migration, and repress apoptosis in vitro, and tumor growth in vivo; Suppress proliferation, colony formation migration, invasion in vitro and induce apoptosis in vitro, and tumor growth in vivo	miR-618/MAEL,miR-765/APE1	[13,30,31]

Figure 5. Biological functions of LINC00511 and relevant molecular mechanisms in malignant tumors.

Deng H, Huang C, Wang Y, et al. LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression. Aging (Albany NY). 2019;11(16):5975–5991.

 PubMedGoogle Scholar

Huang HG, Tang X-L, Huang X-S, et al. Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(8):4232–4245.

 PubMed Web of Science ®Google Scholar

Liu L, Zhu Y, Liu A-M, et al. Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185. Eur Rev Med Pharmacol Sci. 2019;23(17):7457–7468.

 PubMed Web of Science ®Google Scholar

Lu G, Li Y, Ma Y, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 2018;37(1):289.

 PubMedGoogle Scholar

Mao B-DI, Xu P, Zhong Y, et al. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci. 2019;44(2):44.

 PubMed Web of Science ®Google Scholar

Qiao S-C,  Qi K,  Liu C, et al. Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo. J Clin Lab Anal. 2020;34(5):e23164.

 Web of Science ®Google Scholar

Sun -C-C, Li S-J, Li G, et al. Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids. 2016;5(11):e385–e385.

 PubMedGoogle Scholar

Wang J, Wang S-S, Ma H, et al. Expressions clinical signification and prognostic analysis of linc00511 in ovarian cancer tissues. J Pract Med. 2019;35(16):2584–2591.

 Google Scholar

Wang B, Wang Y-Z,  Wang K, et al. Expression and clinical significance of lncRNA LINC00511 in plasma exosome of glioma patients. Chin J Pract Nerv Dis. 2019;22(14):1548–1553.

 Google Scholar

Wang RP, Jiang J, Jiang T, et al. Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(8):3291–3301.

 PubMed Web of Science ®Google Scholar

Yu C-L, Xu X-L, Yuan F. LINC00511 is associated with the malignant status and promotes cell proliferation and motility in cervical cancer. Biosci Rep. 2019;39(9):BSR20190903.

 PubMedGoogle Scholar

Zhao X, Liu Y, Li Z, et al. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2018;22(1):655–667.

 PubMed Web of Science ®Google Scholar

Chen Z, Wu H, Zhang Z, et al. LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIX axis. Cancer Cell Int. 2019;19:351.

 PubMed Web of Science ®Google Scholar

Zhang H, Zhao B, Wang X, et al. LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci. 2019;228:135–144.

 PubMed Web of Science ®Google Scholar

Zhang J, Sui S, Wu H, et al. The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer. Cell Death Dis. 2019;10(8):599.

 PubMedGoogle Scholar

Li C, Liu H, Yang J, et al. Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR-124-3p/CCND2 axis. J Cell Mol Med. 2019;23(6):4386–4394.

 PubMed Web of Science ®Google Scholar

Du X, Tu Y, Liu S, et al. LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. J Cell Mol Med. 2020;24(2):1474–1487.

 PubMed Web of Science ®Google Scholar

Hu W-Y, Wei H-Y, Li K-M, et al. LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis. Biomed Pharmacothe. 2020;121:109642.

 PubMed Web of Science ®Google Scholar

Zhu FY, Zhang S-R, Wang L-H, et al. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1. Eur Rev Med Pharmacol Sci. 2019;23(19):8377–8390.

 PubMed Web of Science ®Google Scholar

Jiang L, Xie X, Ding F, et al. Silencing LINC00511 inhibits cell proliferation, migration and EMT via PTEN/AKT/FOXO1 signaling pathway in lung cancer. Biochem Cell Biol. 2019. DOI:10.1139/bcb-2018-0364

 Google Scholar

Xiang J, Guan Y, Bhandari A, et al. LINC00511 influences cellular proliferation through cyclin-dependent kinases in papillary thyroid carcinoma. J Cancer. 2020;11(2):450–459.

 PubMed Web of Science ®Google Scholar

Chen Y, Bao C, Zhang X, et al. Knockdown of LINC00511 promotes radiosensitivity of thyroid carcinoma cells via suppressing JAK2/STAT3 signaling pathway. Cancer Biol Ther. 2019;20(9):1249–1257.

 PubMed Web of Science ®Google Scholar

Wang K, Zhu G, Bao S, et al. Long non-coding RNA LINC00511 mediates the effects of ESR1 on proliferation and invasion of ovarian cancer through miR-424-5p and miR-370-5p. Cancer Manag Res. 2019;11:10807–10819.

 PubMed Web of Science ®Google Scholar

Wang J, Tian Y, Zheng H, et al. An integrated analysis reveals the oncogenic function of lncRNA LINC00511 in human ovarian cancer. Cancer Med. 2019;8(6):3026–3035.

 PubMed Web of Science ®Google Scholar

Shi Y, Liu M, Huang Y, et al. Promotion of cell autophagy and apoptosis in cervical cancer by inhibition of long noncoding RNA LINC00511 via transcription factor RXRA-regulated PLD1. J Cell Physiol. 2020. DOI:10.1002/jcp.29529

 Web of Science ®Google Scholar

Ding J, Yang C, Yang S. LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2. J Oral Pathol Med. 2018;47(5):468–476.

 PubMed Web of Science ®Google Scholar

Guo W, Yu Q, Zhang M, et al. Long intergenic non-protein coding RNA 511 promotes the progression of osteosarcoma cells through sponging microRNA 618 to upregulate the expression of maelstrom. Aging (Albany NY). 2019;11(15):5351–5367.

 PubMedGoogle Scholar

Yan L-H, Wu X-K,  Liu Y-X, et al. LncRNA Linc00511 promotes osteosarcoma cell proliferation and migration through sponging miR-765. J Cell Biochem. 2018. DOI:10.1002/jcb.27999

 Web of Science ®Google Scholar